6 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Within triple-negative breast cancer, BL2 is a research expression profile associated with growth-factor and myoepithelial programmes. A group-level expression pattern does not establish a drug target or a person's chemotherapy response.
BL2 belongs to the original TNBCtype and refined TNBCtype-4 expression systems. The defining study described growth-factor, metabolic and myoepithelial-associated expression, alongside features shared with BL1. An enriched pathway is not proof that each tumour depends on that pathway.
The 2016 pooled retrospective neoadjuvant analysis reported pCR in 18 percent of BL2 cases (95 percent confidence interval 9 to 28). Masuda's separate retrospective series reported no BL2 pCRs among its subtype groups; 130 TNBC patients overall had standard neoadjuvant treatment and evaluable response. Those historical comparisons are different cohorts, with different classifiers and treatment contexts. A BL2 label alone does not choose an EGFR, MET or PI3K inhibitor or establish modern regimen benefit.
| Setting | Approach | Guideline |
|---|---|---|
| Stage II to III | As for triple-negative disease (KEYNOTE-522 regimen); the low pathological complete response rate in this subtype is a research observation, not a reason to change treatment. | not mapped |